MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

Search

Omeros Corp

Închisă

SectorSănătate

3.93 7.38

Rezumat

Modificarea prețului

24h

Curent

Minim

3.65

Maxim

3.96

Indicatori cheie

By Trading Economics

Venit

-2.1M

-33M

Vânzări

412K

412K

Marjă de profit

-8,121.359

Angajați

202

EBITDA

-1.9M

-35M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+146.58% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-235M

187M

Deschiderea anterioară

-3.45

Închiderea anterioară

3.93

Sentimentul știrilor

By Acuity

30%

70%

66 / 376 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Omeros Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 iul. 2025, 22:19 UTC

Achiziții, Fuziuni, Preluări

FCC Approves U.S. Cellular Sale to T-Mobile

11 iul. 2025, 17:28 UTC

Principalele dinamici ale pieței

SharpLink Gaming Gains on Ethereum Purchase

11 iul. 2025, 16:57 UTC

Câștiguri

BASF Cuts Outlook on Global Economy Uncertainty

13 iul. 2025, 23:54 UTC

Market Talk

Oil Edges Higher Amid Supply Disruption Worries -- Market Talk

13 iul. 2025, 23:49 UTC

Market Talk

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

13 iul. 2025, 23:49 UTC

Market Talk

Global Equities Roundup: Market Talk

13 iul. 2025, 23:40 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

13 iul. 2025, 23:40 UTC

Market Talk

Gold Advances Amid Rising Trade Tensions -- Market Talk

13 iul. 2025, 23:39 UTC

Market Talk

China's Growth Momentum Likely Slowed in 2Q -- Market Talk

13 iul. 2025, 23:16 UTC

Câștiguri

China Shenhua Energy 1H 2024 Net Was CNY32.8B>1088.HK

13 iul. 2025, 23:16 UTC

Câștiguri

China Shenhua Energy: Drop in Coal Prices Weighed on Results >1088.HK

13 iul. 2025, 23:16 UTC

Câștiguri

China Shenhua Energy Sees 1H Net CNY25.6B-Net CNY27.6B >1088.HK

13 iul. 2025, 23:13 UTC

Market Talk

Global Equities Roundup: Market Talk

13 iul. 2025, 23:13 UTC

Market Talk

Ryman Healthcare Could Be Turning a Corner -- Market Talk

13 iul. 2025, 11:00 UTC

Achiziții, Fuziuni, Preluări

The Private-Equity Maneuver Allowing More Investors to Cash Out -- WSJ

12 iul. 2025, 02:24 UTC

Achiziții, Fuziuni, Preluări

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

12 iul. 2025, 02:05 UTC

Achiziții, Fuziuni, Preluări

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

12 iul. 2025, 02:05 UTC

Achiziții, Fuziuni, Preluări

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

12 iul. 2025, 02:05 UTC

Achiziții, Fuziuni, Preluări

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

11 iul. 2025, 21:45 UTC

Market Talk

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 iul. 2025, 19:46 UTC

Achiziții, Fuziuni, Preluări

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 iul. 2025, 19:45 UTC

Market Talk

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 iul. 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 iul. 2025, 18:18 UTC

Market Talk

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 iul. 2025, 17:35 UTC

Market Talk

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 iul. 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 iul. 2025, 16:53 UTC

Market Talk

Crude Futures Add to Early Gains -- Market Talk

11 iul. 2025, 16:42 UTC

Câștiguri

BASF Cuts Outlook on Global Economic Uncertainty

11 iul. 2025, 16:08 UTC

Market Talk

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 iul. 2025, 16:05 UTC

Câștiguri

BASF Will Publish Half-Year Results on July 30

Comparație

Modificare preț

Omeros Corp Așteptări

Obiectiv de preț

By TipRanks

146.58% sus

Prognoză pe 12 luni

Medie 9 USD  146.58%

Maxim 9 USD

Minim 9 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOmeros Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

1

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

6.265 / 7.49Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Weak Bullish Evidence

Sentiment

By Acuity

66 / 376 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.